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Abstract
Background: Glycemic control is a known modifiable risk factor for diabetic foot disease. Prior attempts to define
its relationship with diabetic foot ulcer and Charcot arthropathy fail to account for variability in control and
duration of diabetic disease. We developed a novel metric to reflect aggregate disease exposure in a diabetic,
termed cumulative glycemic burden. We hypothesized that it would be positively associated with both diabetic
foot ulcer and radiographically diagnosed Charcot arthropathy.
Methods: Patients aged 18 to 90 years with ≥3 hemoglobin A1c (HbA1c) values were identified retrospectively at a
single institution over a 15-year period. Primary outcomes were ICD-9 diagnosis of foot ulcer and radiographically
diagnosed Charcot arthropathy. Cumulative glycemic burden was calculated by trapezoidal integration of the area
under a curve defined by HbA1c values above 7 over time. Patients were stratified into quartiles based on
cumulative glycemic burden (excellent, good, fair, and poor control). χ2 tests compared the proportion of foot ulcer
and Charcot across quartiles. Regression analysis identified associated demographic and comorbidity factors with
diabetic foot disease. Statistical significance was set at P < .05.
Results: Out of 22,913 diabetics, 1643 (7.2%) had a foot ulcer; 54 out of 771 diabetics (7.0%) had radiographic
Charcot arthropathy. There was a statistically significant stepwise increase in the incidence of foot ulcer with
increasing cumulative glycemic burden by patient quartile (5.2 vs. 6.4 vs. 7.9 vs. 13.9%; P < .001). No significant trend
was seen between incidence of Charcot arthropathy and greater cumulative glycemic burden (7.8 vs. 5.6 vs. 4.4 vs.
10.0%; P = .469). Peripheral vascular disease was most strongly associated with diabetic foot ulcer. Hypertension and
diabetic neuropathy were independently associated with Charcot arthropathy.
Conclusions: Increasing cumulative glycemic burden is positively associated with diabetic foot ulcer. Greater
attention should be paid towards the most poorly controlled diabetics with the longest duration of disease to
reduce their risk. Cumulative glycemic burden is not associated with Charcot arthropathy.
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Background
It is projected that the prevalence of diabetes in the USA
will nearly double in the next two decades [1]. Based on
recent estimates, 15% of the growing diabetic population
will develop a foot wound in their lifetime, representing
a yearly $39 billion dollar healthcare expenditure [2]. If
not prevented, lower extremity complications related to
diabetes will become an even greater burden on the US
healthcare system [3].
Diabetic foot disease is widely recognized as a signifi-
cant health issue [4]. It is associated with more emer-
gency department visits, hospital admissions, and longer
lengths of stay, in addition to higher rates of amputation
and premature death [5, 6]. Treatment is further compli-
cated by the presence of multiple pre-existing comorbid-
ities. Its substantial morbidity has led to a growing
interest in strategies for earlier recognition and preven-
tion. Still, detection often occurs too late and further in-
vestigation into the identification of at-risk diabetics is
warranted [5, 7, 8].
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Poor metabolic control has long been recognized to
increase risk of diabetic complications, particularly dia-
betic foot disease [9–12]. In registry-based studies, Al-
Rubeaan et al. reported that hemoglobin A1c (HbA1c), a
long-term measure of hyperglycemia, was significantly
higher in diabetics with foot ulcer and Stuck et al. simi-
larly found that the incidence of Charcot arthropathy
more than doubled with increasing HbA1c levels [13].
However, the relationship between diabetic control and
the development of foot ulcer and Charcot arthropathy
remains incompletely defined as existing studies use only
a single baseline HbA1c or serum glucose level as a sur-
rogate for total disease severity [13–15]. To our know-
ledge, no study has previously quantified long-term
glycemic control and its relationship with diabetic foot
disease.
The objective of our study was to develop a longitu-
dinal measure of HbA1c values over time that better es-
timates the cumulative glycemic burden of a diabetic
patient. We hypothesized that our measure would be
positively associated with both diabetic foot ulcer and
radiographically diagnosed Charcot arthropathy.
Methods
The Institutional Review Board at Northwestern University
approved this study prior to initiation.
Patient population
Patients of 18 to 90 years of age with three or more docu-
mented HbA1c values over a 15-year period (2000–2014)
were retrospectively identified through the enterprise data
warehouse (EDW), a centralized infrastructure for unified
electronic patient data at one institution. The cohort of
interest was diabetic patients identified by International
Classification of Diseases (ICD-9) code 250. For each pa-
tient, the total number of HbA1c values and the date that
the values were collected were queried. Patients with dia-
betic foot ulcers were identified via the ICD-9 codes 707.1,
707.10, 707.14, 707.15, and 892.0.
Radiographic analysis
A subset of patients was identified who met the above
criteria and had at least one three-view (AP, lateral, and
oblique) weight-bearing radiographic series of the foot
(right, left, or bilateral) and were seen as an outpatient
by either the senior author or one of two other ortho-
pedic foot and ankle faculty. The most recent radio-
graphic exam was accessed through the Picture
Archiving and Communicating System (PACS) and ex-
amined for evidence of Charcot arthropathy. Radio-
graphic findings of Charcot arthropathy were graded
using the Brodsky classification system with the modifi-
cation by Trepman et al. [16, 17]. Radiographic exams
that included only one or two views of the foot,
intraoperative images, or fluoroscopic images were ex-
cluded. If the patient had evidence of surgery (i.e., fu-
sion), then the most recent pre-operative radiographic
series was evaluated.
Variables
Demographic parameters collected included age, race,
gender, and body mass index (BMI). Current tobacco
use or history of smoking (V15.82), hypertension (401),
peripheral vascular disease (440 with all modifiers), cor-
onary artery disease (414), chronic kidney disease
(585.1–585.6), and diabetes (250) with renal (250.4),
ophthalmic (250.5), and neurological (250.6) manifesta-
tions were among the comorbidities identified via their
respective ICD-9 codes.
Statistical analysis
An initial comparison between patients with and without
diabetes was drawn to better understand the demograph-
ics and comorbidity profile of our cohort of interest. The
two primary outcomes were ICD-9 diagnosis of diabetic
foot ulcer (250.x; 707.1, 707.10, 707.14, 707.15, and 892.0)
and radiographic diagnosis of Charcot arthropathy. Pa-
tients were analyzed by the presence of either primary
outcome. χ2 tests, for categorical variables, and Student’s t
test, for continuous variables, were used to compare
demographic and comorbidity profiles between cohorts.
The primary study objective was the creation of a surro-
gate metric to quantify glycemic burden over time for dia-
betic patients, termed “cumulative glycemic burden”. For
each patient, a curve was derived from their HbA1c levels
greater than the upper limit of adequate glycemic control
(HbA1c = 7) over time [18]. Each patient’s cumulative gly-
cemic burden was calculated by trapezoidal integration of
the area under the curve (AUC) above the x-axis as dem-
onstrated in Fig. 1. The diabetic cohort was then stratified,
via pre-determined cutoffs, into evenly distributed quar-
tiles that represented excellent control, good control, fair
control, and poor control (Table 1.) χ2 tests compared the
proportion of diabetic foot ulcer and Charcot arthropathy
diagnoses among patient quartiles.
Secondary objectives included identifying comorbidi-
ties and patient characteristics independently associated
with diabetic foot ulcer and Charcot arthropathy via re-
gression analysis, which included risk adjustment for
variables identified through univariate screening. P < .05
was considered statistically significant in all studies per-
formed. All analyses were performed using SPSS version
22 (IBM Corp Armonk, NY).
Results
Patient population
Based on our study inclusion criteria, 33,274 patients
were identified, of which 22,913 patients were diabetic
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as determined by ICD-9 diagnosis codes. As demon-
strated in Table 2, patients with diabetes had higher
rates of vascular and kidney disease, were more likely
have a higher mean HbA1c, and more likely to smoke.
Patients with diabetes were further stratified by the pres-
ence of diabetic foot ulcer or radiographic Charcot ar-
thropathy. Out of 22,913 patients, 1643 had diabetic foot
ulcer (7.2%). A total of 771 diabetics had foot radio-
graphs accessible for analysis, of which 517 had X-rays
of their left foot, 531 of their right foot, and 277 of their
bilateral feet. A total of 54 out of 771 patients (7.0%)
were found to have radiographic evidence of Charcot ar-
thropathy. Two patients had bilateral disease. The strati-
fication of disease by the Brodsky classification with
modification by Trepman et al. can be found in Table 3.
Comparisons of baseline characteristics between cohorts
are documented in Tables 4 and 5. In addition to being
more comorbid, the group with foot ulcers were more
likely to be older (62 vs. 66; P < .001) and have a higher
average HbA1c value (7.2 vs. 7.7; P < .001). No significant
differences were detected between the group with and
without Charcot arthropathy. The mean HbA1c values for
patients with and without Charcot arthropathy were not
significantly different (6.5 vs. 6.7; P = .401).
Cumulative glycemic burden
Mean cumulative glycemic burden for patients with foot
ulcer was significantly greater versus patients without
ulcer (2781.5 vs. 1302.8; P < .001). Figure 2 shows a
stepwise increase in the proportion of foot ulcer diagno-
ses across each quartile with increasing cumulative gly-
cemic burden in our diabetic population. The trend was
statistically significant (excellent control 5.2% vs. good
control 6.4% vs. fair control 7.9% vs. poor control 13.9%;
P < .001).
Cumulative glycemic burden for patients with Charcot
arthropathy was not significantly different versus pa-
tients without (1654.66 vs. 1639.83; P = 0.974). Similarly,
no significant trend was observed across patient quar-
tiles in the analysis of Charcot arthropathy (excellent
control 7.8% vs. good control 5.6% vs. fair control 4.4%
vs. poor control 10.0%; P = .469).
Risk factors for diabetic foot ulcer
The strongest associated factor with diabetic foot ulcer
was peripheral vascular disease (odds ratio (OR) 4.31;
3.67–5.06). The variable with the second highest odds
ratio was diabetic neuropathy (OR 3.44; 2.94–4.03).
Other risk factors identified in our regression model in-
cluded diabetic retinopathy, hypertension, coronary ar-
tery disease, and chronic kidney disease. Increasing age
was associated with lower likelihood of ulcer (OR .991;
.985–.997) (Table 6).
Risk factors for Charcot arthropathy
Hypertension and diabetic neuropathy were independ-
ently associated with Charcot arthropathy (OR 2.57;
1.21–4.13) and (OR 1.23; 1.04–3.04). Increasing age was
associated with slightly lower risk of Charcot arthropa-
thy (OR .964; .938–.99) (Table 7).
Discussion
Given the 5-year mortality rate for a diabetic with foot
ulcer between 43 and 55%, an understanding of the dia-
betic disease profile is critical to prevent these devastat-
ing complications [19]. Arguably, one of the most
modifiable risk factors is glycemic control, and prior
Table 1 Range of cumulative glycemic burden per patient
quartile





Fig. 1 Graphical representation of trapezoidal integration for calculation of glycemic burden for a single patient
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attempts to define its relationship with diabetic foot dis-
ease fail to account for variability in glycemic control
and disease duration. In this study, we queried the elec-
tronic medical records at a single institution over a
period of 15 years for all available HbA1c values for a
large diabetic cohort. Employing an area under the curve
method, we developed a novel metric that may serve as
a more accurate measure of lifetime glycemic exposure.
We found that 7.2% of diabetics in our cohort had foot
ulcer, which is similar to previously reported rates [11, 20].
One of the most important findings of our study was
that diabetics with foot ulcer not only had a signifi-
cantly higher mean HbA1c but also a greater cumula-
tive glycemic burden than those without ulcer. Previous
studies have shown that hyperglycemia at one or
multiple time points and duration of diabetic disease
are positively associated with diabetic foot ulcer, but no
study to date has accounted for varying glycemic con-
trol during the time of disease [11, 14, 15, 21, 22]. We
found a statistically significant step-wise increase in the
incidence of foot ulcer with worsening cumulative gly-
cemic burden. Incidence significantly increased from
excellent (5.2%), to good (6.4%), to fair (7.9%), and to
poor control (13.9%) diabetics. Interestingly, the most
dramatic rise occurred from the fair to poor control
quartiles. This would suggest that the most poorly con-
trolled diabetic population with longest duration of dis-
ease may warrant heightened surveillance for ulcers. To
our knowledge, this is the first study to examine the re-
lationship between lifetime diabetic disease burden and
foot disease using a longitudinal measure.
A secondary objective of our study was to identify fac-
tors associated with the diagnosis of foot ulcer or Char-
cot arthropathy. The greatest associated factors with
diabetic foot ulcers were peripheral vascular disease and
peripheral neuropathy [11]. It is known that ischemia
Table 2 Demographics and comorbidities
Diabetic vs. non-diabetic cohort
No diabetes (N = 10,361) Diabetes (N = 22,913) P value
N % N %
Gender
Female 5442 52.6 11,901 51.9 0.306
Male 4913 47.4 11,008 48.1
Race <.001
American Indian or Alaskan Native 14 0.1 61 0.3
Asian 301 2.9 863 3.8
Black or African American 1869 18 5920 25.8
Declined 705 6.8 1625 7.1
Hispanic 62 0.6 152 0.7
Native Hawaiian or other Pacific Islander 10 0.1 17 0.1
Other 1116 10.8 3480 15.2
Unable to answer 8 0.1 5 0
Unknown 634 6.1 693 3
White 5596 54 10,041 43.8
Smoking 3769 38.2 9927 45.5 <.001
Hypertension 5774 55.7 18,569 81 <.001
Peripheral vascular disease 646 6.2 3094 13.5 <.001
Coronary artery disease 1498 14.5 7151 31.2 <.001
Chronic kidney disease 725 7 5216 22.8 <.001
Foot ulcer 133 1.3 1643 7.2 <.001
Age, year 58 (14) 62 (14) <.001
Body mass index 31.5 (26.9) 37.2 (27.4) 0.005
HgA1c, mean 5.5 (.6) 7.4 (2) <.001
Significance defined as P < .05. Continuous variables expressed as mean (standard deviation)
Table 3 Prevalence of Charcot arthropathy
Type 1 Type 2 Type 3A Type 3B Type 4 Type 5 Total
Total 24 10 4 1 15 2 56a
a54 patients with evidence of Charcot arthropathy, 2 patients had
bilateral disease
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predisposes to poor wound healing, worse lower extrem-
ity function, and more frequent non-traumatic amputa-
tion in diabetics [11, 23, 24]. In agreement with a
previous registry-based study, hypertension was also
found to be associated with diabetic foot ulcer [11]. Age,
however, was associated with fewer diabetic foot ulcers
in our study [11, 15, 21, 25, 26]. Lastly, we found no sig-
nificant association between diabetic foot ulcer and BMI,
which is consistent with the majority of available litera-
ture [4, 22, 25, 27, 28]. Still, there is a lack of consensus
in the literature of the relationship between age, BMI,
and diabetic foot ulcer [29]. Additional studies are re-
quired to more clearly define this relationship.
Of the patients who met our inclusion criteria for
radiographic analysis, 7% had Charcot arthropathy. Pre-
vious studies report similar rates in diabetic populations,
ranging from 0.8 to 7.5% [21]. Cumulative glycemic
burden was not statistically greater in patients with
Charcot arthropathy, a finding likely reflective of the ob-
servation that both the group with and without Charcot
arthropathy diagnoses had rather adequate glycemic
control with average HbA1c values of 6.7 and 6.5,
respectively.
A unique finding in our study was the positive inde-
pendent association between hypertension and Charcot
arthropathy. While this finding may be purely incidental
as diabetics often suffer from multiple comorbidities,
hypertension may be a surrogate for a pro-inflammatory
state, which has been shown to contribute to the patho-
genesis of Charcot arthropathy [30]. Lastly, increasing
age was associated with lower incidence of Charcot ar-
thropathy. Previous studies have found an increased in-
cidence in diabetics over the age of 60 and an
association with longer disease duration, while others
Table 4 Demographics and comorbidities
Cohort with foot ulcers vs. cohort without, diabetics only
No foot ulcer (N = 21,270) Foot ulcer (N = 1643) P value
N % N %
Gender
Female 11,204 52.7 697 42.4 <.001
Male 10,063 47.3 945 57.5
Race <.001
American Indian or Alaskan Native 60 0.3 1 0.1
Asian 851 4 12 0.7
Black or African American 5390 25.3 530 32.3
Declined 1562 7.3 63 3.8
Hispanic 143 0.7 9 0.5
Native Hawaiian or other Pacific Islander 17 0.1 0 0
Other 3204 15.1 276 16.8
Unable to answer 4 0 1 0.1
Unknown 678 3.2 15 0.9
White 9307 43.8 734 44.7
Smoking 9098 45 829 51.5 <.001
Diabetic nephropathy 2176 6.9 635 35.8 <.001
Diabetic retinopathy 3461 11 735 41.4 <.001
Diabetic neuropathy 2735 8.7 897 50.5 <.001
Hypertension 16,992 79.9 1577 96 <.001
Peripheral vascular disease 2281 10.7 813 49.5 <.001
Coronary artery disease 6149 28.9 1002 61 <.001
Chronic kidney disease 4300 20.2 916 55.8 <.001
Age, year 62 (15) 66 (13) <.001
BMI 31.8 (7.9) 31.3 (8.9) 0.002
Mean number of HgA1c values drawn 10 (8) 11 (9) <.001
HgA1c, mean 7.2 (1.4) 7.7 (1.6) <.001
Significance defined as P < .05. Continuous variables expressed as mean (standard deviation)
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Table 5 Demographics and comorbidities
Cohort with Charcot arthropathy vs. cohort without, diabetics only
No Charcot (N = 717) Charcot (N = 54) P value
N %Total N %Total
Gender
Female 370 51.6 26 48.1 0.624
Male 347 48.4 28 51.9
Race 0.331
American Indian or Alaskan Native 1 0.1 0 0
Asian 23 3.2 3 5.6
Black or African American 179 25 14 25.9
Declined 75 10.5 8 14.8
Hispanic 7 1 0 0
Native Hawaiian or other Pacific Islander 1 0.1 1 1.9
Other 96 13.4 8 14.8
Unknown 29 4 2 3.7
White 306 42.7 18 33.3
Smoking 255 38.1 21 39.6 0.828
Diabetic nephropathy 62 8.6 2 3.7 0.204
Diabetic retinopathy 96 13.4 5 9.3 0.386
Diabetic neuropathy 76 15.7 7 20 0.103
Hypertension 505 70.4 43 79.6 0.151
Peripheral vascular disease 62 8.6 4 7.4 0.754
Coronary artery disease 180 25.1 16 29.6 0.461
Chronic kidney disease 128 17.9 9 16.7 0.826
Age, year 61 (14) 57 (14) 0.087
BMI 31.7 (7.9) 31.8 (8.7) 0.301
Mean number of HgA1c values drawn 7 (6) 8 (6) 0.512
HgA1c, mean 6.7 (1.5) 6.5 (1.4) 0.401
Significance defined as P < .05. Continuous variables expressed as mean (standard deviation)
Fig. 2 Incidence of foot ulcer and Charcot arthropathy by patient quartile
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show no association with age [13, 14]. Our findings
with regard to age, while meeting statistical signifi-
cance, are likely not clinically significant, and thus,
heightened surveillance for Charcot arthropathy
should be maintained for diabetics in all age groups.
A higher incidence in younger patients would how-
ever support a neurotraumatic etiology for Charcot
arthropathy as younger, more active individuals would
be more prone to repetitive micro-trauma. However,
we were unable to measure activity level in our co-
hort in order to support this hypothesis; thus, further
studies are warranted.
Our study must be interpreted in the context of its
limitations. We collected and analyzed data retrospect-
ively for a large intra-institutional sample size of over
20,000 patients. Given the retrospective nature of our
study, we cannot draw any conclusive causal relation-
ships particularly in the absence of known timing of
diagnoses and linear follow-up of subjects. Conclusions
drawn through univariate analysis should be interpreted
cautiously given the numerous confounding factors. As
with all observational studies, patient demographic,
comorbidities, and diagnoses were collected using diag-
nostic codes from medical records. These may not ac-
curately represent patients’ actual clinical status;
however, all associated conditions found are well recog-
nized in the literature. While the use of ICD-10 coding
may maximize usefulness to future generations, our data
was selected with ICD-9 coding in order to collect a ro-
bust population of patients.
Patients with and without a diagnosis of foot ulcer
or Charcot arthropathy may fall into different defined
quartiles of glycemic control at different times, which
may over- or underestimate the associations uncov-
ered in our study. The fluctuating nature of glycemic
control requires a fluid metric, such as cumulative
glycemic burden, that accounts for both time and
change in HbA1c. Moreover, it is possible that vari-
ability in the precision of the trapezoidal integration
method, which was used to calculate cumulative gly-
cemic burden, exists due to inclusion of patients with
at least three recorded HbA1c values, but no max-
imum limit. However, the difference in mean number
of HbA1c values available for patients with and with-
out the presence of foot ulcer (11 vs. 10), as well as
with and without the presence of radiographic Char-
cot arthropathy (8 vs. 7), was not clinically significant.
It is also possible that variability in patient follow-up
may have affected measured values of cumulative gly-
cemic burden. We therefore acknowledge that our
measure, as applied in this investigation, is subject to
some degree of error.
For our radiographic analysis, the inclusion of diabetics
who at one time had been evaluated in an outpatient
orthopedic foot and ankle clinic creates selection bias,
which may have led to an overestimation of the incidence
of Charcot arthropathy in our diabetic population. Acute
cases diagnosed solely on non-radiographic, clinical pa-
rameters (presence of swelling, erythema, warmth, etc.)
may have been missed due to our methodology.
Finally, interventions upon diagnosis of the foot
ulcer including off-loading and casting and the com-
pliancy of subjects in optimizing their glycemic con-
trol are unknown. The authors emphasize that the
objective of the study was to simply determine the as-
sociation between cumulative glycemic burden and
diabetic foot disease incidence.
Conclusions
Increasing cumulative glycemic burden is positively as-
sociated with diabetic foot ulcer. Greater attention
should be paid towards the most poorly controlled dia-
betics with the longest duration of disease to reduce
their risk of diabetic foot ulcers. Cumulative glycemic
burden is not associated with Charcot arthropathy.
Table 6 Associated risk factors of diabetic foot ulcer
Odds
ratio
95% confidence interval P value
Lower Upper
Agea 0.991 0.985 0.997 0.003
Number of A1C’s drawn 0.996 0.989 1.003 0.263
Most recent BMI 1 0.999 1.001 0.556
Diabetic retinopathy 1.357 1.154 1.595 <.001
Diabetic neuropathy 3.441 2.94 4.027 <.001
Hypertension 2.265 1.586 3.237 <.001
Peripheral vascular disease 4.309 3.668 5.062 <.001
Coronary artery disease 1.388 1.178 1.635 <.001
Chronic kidney disease 1.824 1.541 2.158 <.001
aRepresents odds ratio for every year increase in age
Table 7 Associated risk factors of Charcot arthropathy
Odds
ratio
95% confidence interval P value
Lower Upper
Agea 0.964 0.938 0.99 0.008
Number of A1c’s drawn 1.01 0.967 1.056 0.65
Most recent BMI 1.02 0.976 1.034 0.284
Hypertension 2.571 1.213 4.131 0.018
Diabetic neuropathy 1.233 1.035 3.038 0.049
Diabetic retinopathy 0.613 0.231 1.631 0.327
Peripheral vascular disease 0.751 0.245 2.296 0.615
Coronary artery disease 1.272 0.66 2.451 0.472
Chronic kidney disease 0.891 0.392 2.023 0.782
aRepresents odds ratio for every year increase in age
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